A guided first visit
Choose the question that brought you here.
Each path begins with context, then moves through three already-published reads. The reason for every step is visible, so you can follow the sequence or leave it at any point.
Path 01
New to longevity science
Learn the map, then practice separating evidence maturity from a headline.
- Start
What is longevity research?
Start with the vocabulary and the layers that connect a result to a reader-facing claim.
Orientation guide · Field map and core distinctions - Next
How strong is the evidence?
Next, see why a mechanism, biomarker, association and clinical outcome answer different questions.
Evidence guide · Cells, animals, human studies and outcomes - Then
Exercise and healthy aging
Apply those distinctions to a mature human evidence base without turning broad benefit into a lifespan guarantee.
Evidence explainer · Human function, disease risk and mortality - Compare
Partial reprogramming reaches a human safety trial
Finish by contrasting that mature evidence with a genuinely experimental program.
Research analysis · Early human safety testing and animal evidence
Path 02
Everyday life
Move from a broad category to studies of exercise, mobility and eating patterns.
- Start
Everyday foundations
Start with the complete category so a single study does not stand in for the whole evidence base.
Topic hub · Exercise, sleep and eating patterns - Next
Exercise and healthy aging
See the broad human evidence and the boundary between healthier aging and proven lifespan extension.
Evidence explainer · Human function, disease risk and mortality - Then
Physical activity and late-life mobility
Narrow the question to one randomized program and one concrete functional outcome.
Research analysis · Mobility disability in at-risk older adults - Compare
The randomized MIND diet trial
Compare a different everyday intervention where the active control changed what the result means.
Research analysis · Human cognition and MRI outcomes
Path 03
Drugs & supplements
Compare null, mixed and early signals without treating category membership as endorsement.
- Start
Drugs & supplements
Start with the category boundaries, safety notes and complete released coverage.
Topic hub · Ten published evidence reviews - Next
Omega-3 cardiovascular evidence
See why results from unlike formulations and populations should not be collapsed into one verdict.
Evidence explainer · Different formulations and cardiovascular outcomes - Then
Vitamin D and the VITAL trial
Separate an essential nutrient and deficiency care from a broad prevention claim.
Claim check · Primary prevention in generally healthy adults - Compare
Rapamycin and the PEARL trial
Finish with an intervention whose human longevity evidence remains early and limited.
Research brief · Small human feasibility and safety trial
Path 04
Experimental science & aging measurements
Follow the translation chain from models and measurements to bounded human claims.
- Start
From models to people
Start with the questions that determine whether a model result can transfer to people.
Translation guide · Cells, organisms, exposure, outcomes and safety - Next
How to read an aging biomarker
Then separate a measurable change from a validated health outcome.
Measurement guide · Validity, surrogacy, function and lifespan - Then
Partial reprogramming reaches a human safety trial
Apply the translation questions to an experimental biotechnology entering human study.
Research analysis · Early human safety testing and animal evidence - Compare
What epigenetic clocks can—and cannot—measure
Finish with a measurement story where prediction and proven intervention benefit remain distinct.
Evidence explainer · Human aging biomarkers